Forus
The AI network closing the gap between prescription and treatment — from Tandem to Forus, a new infrastructure layer in U.S. drug distribution
We view Forus’s origin as a case of payer-side experience translating directly into a provider-side product thesis. Forus — operating as Tandem until May 2026 — was founded in New York in 2023 by Sahir Jaggi. Jaggi holds a biomedical research degree from Columbia University and, prior to founding the company, served as Director of Product Strategy and Product Lead for Care Delivery and Patient Experience at Oscar Health. In our read, this background gave him a payer-side vantage point on the structural bottlenecks connecting prescribing, insurance, and pharmacy fulfillment well before he set out to build a company around them.
We flag that Bain Capital Ventures has backed the company since its seed round, making it the longest-standing institutional investor on the cap table. Bain Capital Ventures General Partner Kevin Zhang noted in the Series C announcement that the largest companies in medicine have turned to Forus to deliver their newest treatments to patients, and framed the next era of medicine as running on the network Forus is building. We read three consecutive rounds of lead or follow-on participation from a seed-stage investor as a reasonably strong signal of institutional conviction in the founding team, though we note this remains a private-market assessment untested by public markets.
Biomedical research degree, Columbia University. Former Director of Product Strategy and Product Lead for Care Delivery and Patient Experience at Oscar Health. Reported to have been a partner at Rough Draft Ventures, General Catalyst’s student-run venture program — a detail we view as a plausible explanation for General Catalyst’s early conviction in the company. Founded Forus (as Tandem) in 2023. Reported as 31 years old at the time of the company’s May 2026 public launch.
Data integrity note: We found no public disclosure of a co-founder; Sahir Jaggi is the only officially confirmed founder in available materials. The company rebranded from Tandem to Forus in May 2026, coinciding with the end of its stealth period and the announcement of nationwide scale.
Forus is an AI infrastructure company that connects physicians, pharmacies, payers, and biopharma into a single network designed to remove the administrative friction sitting between a prescription and treatment initiation. The core product thesis assigns a dedicated AI agent to every prescription; each agent handles prior authorization, appeals, enrollment in financial-assistance programs, and pharmacy routing — effectively the full span of steps between a clinical decision and a patient’s first dose. The platform is embedded directly in provider EHR workflows and is offered free of charge to both providers and patients.
| Area | Status | Stage | Notes |
|---|---|---|---|
| First launched specialty | Over 1/3 of nationwide providers adopted | Scaled | Specific specialty not named in company materials; we assess this as having reached scale stage |
| Rheumatology | Live case study disclosed (Virginia Rheumatology Clinic) | Live | Press-reported approval turnaround compressed to under two days |
| Gastroenterology | Strategic partnership with the American Gastroenterological Association | Live | Announced July 2026; targets 60M+ Americans with digestive disease |
| Additional specialties | Double-digit-percentage adoption and ramping | Ramping | Series C proceeds earmarked for expansion to all specialties and care settings |
| Biopharma partnerships | 9 of top 15 global pharma companies plus multiple growth-stage biotechs | Enterprise | OpenEvidence integration (April 2026) extends the partnership upstream into prescription generation |
Data integrity note — revenue model: The company has not publicly disclosed revenue figures or the mechanics of its monetization model (biopharma fees, payer arrangements, or otherwise). Trade newsletters (AlleyWatch, cited by onhealthcare.tech) have floated an unconfirmed estimate of roughly $50M in 2026 annualized revenue. This figure originates from third-party commentary rather than company disclosure and should not be treated as verified data.
Two features of Forus’s fundraising trajectory stand out to us. First, the valuation moved from $1B in January 2026 to $3B in September 2026 — a roughly threefold increase in about seven months. Second, every existing institutional investor (Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures, SV Angel) participated in the Series C. We read the latter as a signal of strong insider conviction; the former, in our view, introduces valuation-premium risk that warrants scrutiny.
Sahir Jaggi founded Tandem (now Forus) in New York. Bain Capital Ventures is confirmed as a seed-stage investor, establishing a long-term relationship that later culminated in its lead role in the Series C. Forbes has reported a seed round of approximately $7M, though we could not verify this figure against company disclosure.
We could not confirm the exact size, timing, or lead investor of an intervening Series A round. Given that cumulative funding was reported at approximately $137M as of the January 2026 Series B announcement, meaningful capital likely entered between the seed round and Series B — but we flag this as an inference rather than a confirmed data point.
Led by Accel, with participation from Thrive Capital and General Catalyst. First reported by Bloomberg, the round brought cumulative funding to approximately $137M. At the time, the company still operated as Tandem Technology and was positioned as a prescription-automation AI platform; specific adoption metrics on provider, payer, and EHR integration had not yet been disclosed.
The company rebranded to Forus and announced its formal market entry. Thrive Capital and General Catalyst co-led, with Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC participating, bringing cumulative funding above $160M. Trade coverage (AlleyWatch, as cited) attributed roughly $123M of that figure to a new Series B tranche, but company materials do not clearly distinguish whether this represents an upsize of the January $100M round or a separate extension.
Led by Bain Capital Ventures, an investor since seed. Every existing institutional investor reinvested (Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC), with Vast Ventures and SV Angel joining as new participants. Valuation rose from $1B to $3B in roughly seven months. Stated use of proceeds includes expansion into all specialties and care settings, extending AI agent capability across the full path to treatment, and accelerating team hiring.
- Expand the platform to all specialties and care settings
- Extend AI agent capability across the full path from prescription to treatment
- Accelerate team hiring
The prior-authorization and medication-access automation market is crowded, with well-capitalized incumbents including CoverMyMeds (McKesson-backed), Surescripts, Rhyme (formerly PriorAuthNow), Cohere Health, Availity AuthAI, Myndshft, Waystar, SamaCare, and Infinitus. We set out below the six dimensions on which we view Forus as structurally differentiated within this field.
Connects physicians, pharmacies, payers, and biopharma on a single network, versus point solutions like Cohere Health (payer-side only) or CoverMyMeds (pharmacy PA-centric). Integrated data and workflow across the full chain has the potential to function as a structural moat.
Triggers automatically at the moment a prescription is written rather than intervening only after a rejection. This design requires no incremental action from clinicians and, in our view, structurally lowers post-adoption churn.
Zero cost to providers and patients effectively removes the supply-side adoption barrier, underpinning the rapid expansion to all 50 states and 85% ZIP code coverage. This model, however, means long-run monetization depends entirely on payer- or biopharma-side charges — a point we revisit as a risk in Section 5.
Functions like a case manager assigned to each individual prescription, reasoning through patient history, insurance coverage, and financial circumstances to determine next steps, drawing on clinical models, specialized sub-agents, and a growing corpus of prior cases.
Works with 9 of the top 15 global pharmaceutical companies, feeding real-world usage data into clinical trial design, launch strategy, and investment decisions on harder-to-treat conditions. As the network scales, the value of this data to biopharma partners compounds.
CMS operational requirements around electronic prior authorization took effect January 1, 2026, with mandatory FHIR-based Prior Authorization APIs due January 1, 2027. We view this shift toward electronic, standardized workflows as structurally favorable to an AI-native platform like Forus.
What Bain Capital Ventures’ continued backing signals: Bain Capital Ventures has invested across every round from seed through Series C and led the latest raise. We read this as more than a financial bet — it suggests a long-horizon thesis that Forus becomes the default infrastructure layer for medication access. That said, this remains a private-market judgment that has not been tested against public-market valuation discipline.
As of its September 2026 Series C, Forus remains a private healthcare AI infrastructure company with no disclosed revenue or profitability metrics. We present opportunity and risk factors below on a balanced basis and flag any unverified figures separately.
On the opportunity side, we highlight: ▲ substantial room to expand beyond the specialties (rheumatology, gastroenterology, and one undisclosed launch specialty) that have reached scale, implying an early-stage penetration of total addressable market; ▲ existing relationships with 9 of the top 15 global pharmaceutical companies as a plausible base for expanding enterprise contracts; ▲ the 2027 FHIR API mandate and broader CMS interoperability push as a regulatory tailwind for AI-native platforms; ▲ full reinvestment by every existing institutional investor from seed through Series C, which we read as a strong insider-conviction signal.
Valuation escalation risk: The move from $1B to $3B in roughly seven months embeds a substantial premium on future growth expectations. A growth slowdown or a valuation reset at a later round or IPO would carry down-round risk.
Competitive intensity: Well-capitalized incumbents — CoverMyMeds (McKesson-affiliated), Surescripts, Cohere Health, Rhyme, Availity AuthAI, Myndshft, and Waystar among them — already operate in this market, and several are already affiliated with large healthcare enterprises with established distribution.
Revenue-model opacity: The company has not publicly disclosed its revenue or monetization structure. The widely cited ~$50M ARR estimate originates from trade newsletters rather than company disclosure and should be treated as unverified.
Sustainability of the free model: Free access for providers and patients has clearly supported rapid adoption, but it makes monetization entirely dependent on payer- or biopharma-side fee arrangements. The scale and durability of that charging structure remain unverified in public materials.
Dependence on private capital: As a pre-IPO company, Forus remains dependent on continued venture funding to sustain growth. A shift in capital-market conditions could affect the terms of future rounds.
Data and compliance exposure: Given the volume of patient medical and insurance data the platform processes, tightening HIPAA-related privacy requirements or a data-security incident would carry meaningful reputational and legal risk.